Enjaymo Marks Latest Milestone In Sanofi’s Blood Disorder Effort
The company plans to draw on experience with other rare blood disorder drug launches, but pointed to some differences in the market for cold agglutinin disease.
You may also be interested in...
Its crunch time for sponsors of more than a dozen products as the EMA meets to adopt opinions on several marketing authorization applications.
Star will employ a hub-and-spoke model to launch portfolio companies focused on specific biological areas. The first company, Electra, will emphasize unmet medical needs and therapies that can address multiple diseases.
Sanofi’s decision is influenced by its own in-house options, but also by the growing competition in sickle cell gene therapy.